ST. LOUIS, May 14, 2020 — The Institute for Clinical and Economic Review (ICER) announced the appointment of Angela Fleming Brown, CEO of the St. Louis Regional Health, to one its three independent Appraisal Councils – the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC).
“Each of the independent Appraisal Councils plays a vital role,” noted Steven D. Pearson, MD, MSc, President of ICER. “As experts in evaluating evidence across many fields, they bring a sharp eye to judgments about the strengths and limitations of evidence on the comparative clinical effectiveness of different health care interventions. Through their public deliberations, the Appraisal Councils also have the opportunity to hear further input directly from patient representatives, clinical experts, and other stakeholders. In their deliberations and votes the Appraisal Councils integrate these considerations, thereby bringing into the open many of the key issues that insurers and other policymakers will be weighing. The Appraisal Councils thus can improve the transparency, and the inclusivity, of the process through which evidence is interpreted and translated into pricing and access decisions.”
Appraisal Councils are regionally-based experts in areas including outcomes research, health economics, technology assessment, medical ethics, patient access and advocacy, and clinical practice. Council members are chosen based on their expertise in reviewing and applying medical evidence in a variety of contexts and are not selected based on their specific expertise in a given clinical area. All members must meet strict conflict of interest criteria to participate in ICER’s meetings.
“I have spent my career at the St. Louis Regional Health Commission advocating for health care access for our region’s most vulnerable patients,” said Brown. “I look forward to sharing best practices with the Midwest CEPAC.”
About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.